Plain-English translation of NCT07334743 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are looking for new biological markers in blood that could help track amyotrophic lateral sclerosis (ALS) and measure whether experimental treatments are working. They will collect blood samples and spinal fluid from people newly diagnosed with ALS and compare them to healthy volunteers. These markers could make it faster and safer to test new ALS therapies in the future.
Currently, there are no reliable blood tests that can tell doctors whether an ALS treatment is actually working or how quickly the disease is progressing. This study aims to find measurable signs in the blood that could serve as 'biomarkers'—signals that show whether a patient is responding to treatment—so future ALS drug trials can be faster and give clearer answers.
You likely qualify if…
You likely don't qualify if…
If you have suspected ALS, you will have a baseline visit at the hospital where you'll undergo standard diagnostic testing (nerve tests, MRI, breathing tests, spinal tap, and blood draws) plus additional research blood samples. You'll then return for follow-up visits at 6, 12, 18, and 24 months with repeat blood draws and clinical testing. If you're a healthy volunteer, you'll have one visit to donate blood and undergo one brief brain scan.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
France